Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Solid Tumors.

Next Previous
X
Search
Trial Profile

A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Solid Tumors.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glasdegib (Primary)
  • Indications Basal cell cancer; Cervical cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pfizer

    • Most Recent Events

    • 24 Sep 2020 Results (n=272) of pooled analysis of three clinical studies ((B1371001or NCT00953758), (B1371002 or NCT01286467) and (B1371003 or NCT01546038)) assessing evaluation of the relationship of Glasdegib exposure and safety end points in patients with refractory solid tumors and hematologic malignancies, published in the Journal of Clinical Pharmacology.
    • 25 Nov 2019 Results of a population pharmacokinetics analysis and data were pooled from three clinical glasdegib studies; (n=47 ; B1371001or NCT00953758), (n=23 ; B1371002 or NCT01286467) and (n=202 ; B1371003 or NCT01546038) were published in the Journal of Clinical Pharmacology
    • 14 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top